| Literature DB >> 30250212 |
Jesse Slone1, Yanyan Peng1, Adam Chamberlin2, Belinda Harris3, Julie Kaylor4, Marie T McDonald5, Monica Lemmon5, Mays Antonine El-Dairi6, Dmitry Tchapyjnikov5, Laura A Gonzalez-Krellwitz7, Elizabeth A Sellars4, Allyn McConkie-Rosell5, Laura G Reinholdt3, Taosheng Huang8,9.
Abstract
Mitochondrial dysfunction lies behind many neurodegenerative disorders, owing largely to the intense energy requirements of most neurons. Such mitochondrial dysfunction may work through a variety of mechanisms, from direct disruption of the electron transport chain to abnormal mitochondrial biogenesis. Recently, we have identified biallelic mutations in the mitochondrial flavoprotein "ferredoxin reductase" (FDXR) gene as a novel cause of mitochondriopathy, peripheral neuropathy, and optic atrophy. In this report, we expand upon those results by describing two new cases of disease-causing FDXR variants in patients with variable severity of phenotypes, including evidence of an inflammatory response in brain autopsy. To investigate the underlying pathogenesis, we examined neurodegeneration in a mouse model. We found that Fdxr mutant mouse brain tissues share pathological changes similar to those seen in patient autopsy material, including increased astrocytes. Furthermore, we show that these abnormalities are associated with increased levels of markers for both neurodegeneration and gliosis, with the latter implying inflammation as a major factor in the pathology of Fdxr mutations. These data provide further insight into the pathogenic mechanism of FDXR-mediated central neuropathy, and suggest an avenue for mechanistic studies that will ultimately inform treatment.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30250212 PMCID: PMC6451867 DOI: 10.1038/s10038-018-0515-y
Source DB: PubMed Journal: J Hum Genet ISSN: 1434-5161 Impact factor: 3.172